Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066792 · ClinicalTrials.gov registry record · Early Phase 1
Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
A Early Phase 1 study, sponsored by Jasper A. Smits.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 152
- Enrollment target
NCT02066792 is a Early Phase 1 study that has completed, run by Jasper A. Smits. The registered enrollment target is 152 participants.
The verdict
NCT02066792, a Early Phase 1 study, has completed, sponsored by Jasper A. Smits.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the efficacy of 50 mg of d-cycloserine in comparison to placebo (a pill containing no medication) for improving the effectiveness of cognitive-behavioral therapy (CBT) in reducing symptoms associated with social anxiety disorder. In addition, the study will examine whether the effectiveness of d-cycloserine depends on the timing of the pill administration (i.e., 1- hour before the session or immediately after the session) as well as the success of the CBT therapy sessions. The investigators hypothesize that the tailored post-session DCS administration condition will outperform the other conditions (pre-session DCS, placebo, and non-tailored post-session DCS). This will be evidenced by short- and long-term improvements in social anxiety severity.
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive Behavioral Therapy
- DRUG D-Cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066792
The ClinicalTrials.gov registry entry for NCT02066792 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jasper A. Smits, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02066792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02066792 about?
NCT02066792 is a clinical study titled "Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder". The purpose of this study is to examine the efficacy of 50 mg of d-cycloserine in comparison to placebo (a pill containing no medication) for improving the effectiveness of cognitive-behavioral therapy (CBT) in reducing symptoms associated with social anxiety disorder. In addition, the study will ex...
What is the current status of trial NCT02066792?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 152 participants. The study started on 2014-04. Estimated completion is 2018-07-01.
What interventions are being tested in trial NCT02066792?
The interventions under investigation include: Placebo (DRUG), Cognitive Behavioral Therapy (BEHAVIORAL), D-Cycloserine (DRUG).
Who is sponsoring clinical trial NCT02066792?
This trial is sponsored by Jasper A. Smits, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.